4.7 Article

PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma

Journal

BRITISH JOURNAL OF CANCER
Volume 112, Issue 12, Pages 1938-1943

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.169

Keywords

Papillary thyroid cancer; PTEN; Follicular variant

Categories

Ask authors/readers for more resources

Background: PTEN gene at chromosomes 10q23.3 is a tumour suppressor gene that is inactivated in many types of human cancers. The known mechanisms of PTEN inactivation are rendered to mutation, epigenetic silencing by aberrant methylation or gene deletion. Although PTEN role has been documented in many cancers, PTEN alteration in papillary thyroid carcinoma (PTC) has not been fully elucidated. The aim of this study is to comprehensively investigate PTEN alterations in a large cohort of Middle Eastern papillary thyroid cancer by immunohistochemistry and fluorescent in situ hybridisation (FISH). Methods: PTEN protein expression was analysed by immunohistochemistry in a tissue microarray (TMA) format in a large cohort of more than 1000 patients with papillary thyroid cancer. Copy number changes in PTEN were analysed by FISH and data were correlated with clinicopathological parameters along with survival analysis. Results: PTEN inactivation reflected by complete absence of staining was seen in 24.5% of PTC samples, whereas PTEN deletion was seen only in 4.8% of the tested samples by FISH. No association was seen between PTEN loss of protein expression and PTEN gene deletion. However, interestingly, PTEN loss of expression was significantly associated with the follicular variant subset of papillary thyroid cancer. Conclusion: Our study confirmed that PTEN might have a role in pathogenesis in a subset of PTC. PTEN loss of protein expression is a more common event in follicular variant of papillary thyroid cancer. Lack of association between PTEN loss of protein expression and PTEN gene deletion might indicate that gene deletion may not be the sole cause for PTEN loss of expression and these results might raise the possibility of other mechanism such as promoter methylation-mediated gene silencing to be responsible for PTEN inactivation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Genetics & Heredity

Pitfalls in Cutaneous Melanoma Diagnosis and the Need for New Reliable Markers

Giang T. Lam, Sarita Prabhakaran, Alexandra Sorvina, Carmela Martini, Ben S. -Y. Ung, Litsa Karageorgos, Shane M. Hickey, Joanna Lazniewska, Ian R. D. Johnson, Desmond B. Williams, Sonja Klebe, Victoria Malone, John J. O'Leary, Louise Jackett, Doug A. Brooks, Jessica M. Logan

Summary: Accurate diagnosis of melanoma is crucial for patient outcomes. However, subjective interpretation of histopathologic analysis and the difficulty in distinguishing melanoma from benign lesions using immunohistochemistry pose challenges. The lack of specific biomarkers further complicates accurate diagnosis.

MOLECULAR DIAGNOSIS & THERAPY (2023)

Article Endocrinology & Metabolism

Bilateral multifocality is an independent predictor of patients' outcome in Middle Eastern papillary thyroid carcinoma

Sandeep Kumar Parvathareddy, Abdul K. Siraj, Padmanaban Annaiyappanaidu, Nabil Siraj, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya

Summary: This study retrospectively analyzed 1283 patients with papillary thyroid carcinoma (PTC) and found a high incidence of bilateral multifocality. Bilateral multifocality was closely associated with clinical pathological characteristics such as age, gender, tumor size, and lymph node metastasis. It was also identified as an independent predictor of PTC recurrence. Therefore, patients with bilateral multifocal PTC may benefit from more frequent follow-up to detect recurrences earlier.

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Oncology

Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling

Pratheesh Kumar Poyil, Abdul K. Siraj, Divya Padmaja, Sandeep Kumar Parvathareddy, Roxanne Diaz, Saravanan Thangavel, Rafia Begum, Wael Haqawi, Falah Hassan Al-Mohanna, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya

Summary: This study investigated the expression and functional role of furin in Middle Eastern papillary thyroid carcinoma (PTC). Furin overexpression was observed in 44.6% of PTC cases and was associated with aggressive clinicopathological parameters and poor outcomes. Knockdown of FURIN suppressed tumor growth, migration, invasion, and epithelial-to-mesenchymal transition (EMT) in BRAF mutant cells, while overexpression of FURIN reversed these effects in BRAF wild-type cells. FURIN inhibition showed a synergistic antitumor effect with anti-MEK inhibitor treatment.

MOLECULAR ONCOLOGY (2023)

Article Pathology

Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread

Alexandra Sorvina, Carmela Martini, Sarita Prabhakaran, Jessica M. Logan, Benjamin S-Y. Ung, Courtney Moore, Ian R. D. Johnson, Joanna Lazniewska, Prerna Tewari, Victoria Malone, Robert D. Brooks, Shane M. Hickey, Maria C. Caruso, Sonja Klebe, Litsa Karageorgos, John J. O'leary, Brett Delahunt, Hemamali Samaratunga, Doug A. Brooks

Summary: The presence of intraductal carcinoma of the prostate (IDCP) is associated with late-stage disease and poor outcomes. However, accurately assessing disease severity remains a challenge. Current markers have limited utility in characterizing the complex biology of IDCP.

PATHOLOGY (2023)

Article Multidisciplinary Sciences

PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients

Abdul K. K. Siraj, Rong Bu, Sandeep Kumar Parvathareddy, Kaleem Iqbal, Saud Azam, Zeeshan Qadri, Maha Al-Rasheed, Wael Haqawi, Mark Diaz, Ingrid G. G. Victoria, Ismail A. A. Al-Badawi, Asma Tulbah, Fouad Al-Dayel, Dahish Ajarim, Khawla S. S. Al-Kuraya

Summary: By screening 918 breast cancer/ovarian cancer patients from Saudi Arabia, we identified six cases with pathogenic/likely pathogenic variants in the PALB2 gene, accounting for 0.65% of the entire cohort. Among these cases, two carried pathogenic variants and four carried likely pathogenic variants. All affected carriers had breast cancer, with a median age of diagnosis at 39.5 years, and only two cases had a documented family history of cancer.

SCIENTIFIC REPORTS (2023)

Article Oncology

Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1

Jessica M. Logan, Ashley M. Hopkins, Carmela Martini, Alexandra Sorvina, Prerna Tewari, Sarita Prabhakaran, Chelsea Huzzell, Ian R. D. Johnson, Shane M. Hickey, Ben S. -Y. Ung, Joanna Lazniewska, Robert D. Brooks, Courtney R. Moore, Maria C. Caruso, Litsa Karageorgos, Cara M. Martin, Sharon O'Toole, Laura Bogue Edgerton, Mark P. Ward, Mark Bates, Stavros Selemidis, Adrian Esterman, Sheena Heffernan, Helen Keegan, Sarah Ni Mhaolcatha, Roisin O'Connor, Victoria Malone, Marguerite Carter, Katie Ryan, Andres Clarke, Nathan Brady, Sonja Klebe, Hemamali Samaratunga, Brett Delahunt, Michael J. Sorich, Kim Moretti, Lisa M. Butler, John J. O'Leary, Douglas A. Brooks

Summary: A novel biomarker panel (Appl1, Sortilin and Syndecan-1) was found to be a strong independent predictor for both clinical and biochemical recurrence outcomes, with higher prediction performance than traditional grading. The study also found that biomarker-assisted assessment had better predictive performance for evaluating the risk of biochemical recurrence and clinical recurrence in patients with prostate cancer.

CANCERS (2023)

Article Pathology

Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study

Prudence A. Russell, Alexandra L. Farrall, Sarita Prabhakaran, Khashayar Asadi, Wade Barrett, Caroline Cooper, Wendy Cooper, Samuel Cotton, Edwina Duhig, Matthew Egan, Stephen Fox, David Godbolt, Shilpa Gupta, Aniza Hassan, Connull Leslie, Trishe Leong, David Moffat, Min Ru Qiu, Vanathi Sivasubramaniam, Joanna Skerman, Cameron Snell, Michael Walsh, Karen Whale, Sonja Klebe

Summary: This study investigated the real-world prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC) in Australia. The findings revealed associations between PD-L1 expression and gender, age, and tumor stage. Additionally, significant differences were observed among different sample types, such as cytology and biopsy samples.

PATHOLOGY (2023)

Correction Pathology

Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer (Sept, 10.1007/s00428-023-03643-1, 2023)

Carmela Martini, Jessica M. Logan, Alexandra Sorvina, Sarita Prabhakaran, Benjamin S-Y. Ung, Ian R. D. Johnson, Shane M. Hickey, Robert D. Brooks, Maria C. kConFab Consortium, Maria C. Caruso, Sonja Klebe, Litsa Karageorgos, John J. O'Leary, Brett Delahunt, Hemamali Samaratunga, Douglas A. Brooks

VIRCHOWS ARCHIV (2023)

Article Multidisciplinary Sciences

Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression

Joanna Lazniewska, Ka Lok Li, Ian R. D. Johnson, Alexandra Sorvina, Jessica M. Logan, Carmela Martini, Courtney Moore, Ben S. -Y. Ung, Litsa Karageorgos, Shane M. Hickey, Sarita Prabhakaran, Jessica K. Heatlie, Robert D. Brooks, Chelsea Huzzell, Nicholas I. Warnock, Mark P. Ward, Bashir Mohammed, Prerna Tewari, Cara Martin, Sharon O'Toole, Laura Bogue Edgerton, Mark Bates, Paul Moretti, Stuart M. Pitson, Stavros Selemidis, Lisa M. Butler, John J. O'Leary, Douglas A. Brooks

Summary: The development and progression of prostate cancer are closely related to the regulation of glucose and lipid metabolism, as well as alterations in androgen receptor expression and signaling. This study reveals a previously unrecognized molecular mechanism for prostate cancer, which involves the dynamic balance between sortilin and syndecan-1 and their impact on different metabolic phenotypes. In androgen-sensitive cells, sortilin enhances glucose metabolism while limiting lipid metabolism, whereas in androgen-insensitive cells, syndecan-1 promotes lipid metabolism. Additionally, androgen-deprived cells show decreased expression of sortilin and increased expression of syndecan-1, contributing to altered glucose and lipid metabolism. These findings have important implications for understanding disease progression and castration-resistant prostate cancer in the context of androgen-deprivation therapy.

SCIENTIFIC REPORTS (2023)

Article Oncology

Altered endosomal-lysosomal biogenesis in melanoma

Giang T. Lam, Alexandra Sorvina, Carmela Martini, Sarita Prabhakaran, Ben S. -Y. Ung, Joanna Lazniewska, Courtney R. Moore, Andrew R. Beck, Ashley M. Hopkins, Ian R. D. Johnson, Maria C. Caruso, Shane M. Hickey, Robert D. Brooks, Louise Jackett, Litsa Karageorgos, Erwin J. Foster -Smith, Victoria Malone, Sonja Klebe, John J. O'Leary, Douglas A. Brooks, Jessica M. Logan

Summary: Cutaneous melanoma is a lethal form of skin tumor. Current detection methods based on melanin visualization cannot reliably distinguish between different types of lesions. This study investigates the involvement of the endosomal-lysosomal system in melanoma and identifies dysregulated genes associated with this system, which may serve as potential markers for differentiating melanoma from other skin cancers.

NEOPLASIA (2023)

Article Oncology

Whole Exome-Wide Association Identifies Rare Variants in GALNT9 Associated with Middle Eastern Papillary Thyroid Carcinoma Risk

Rong Bu, Abdul K. Siraj, Saud Azam, Kaleem Iqbal, Zeeshan Qadri, Maha Al-Rasheed, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya

Summary: This study identified a strong association between GALNT9 gene and rare inactivating variants in Middle Eastern population with Papillary thyroid carcinoma (PTC), and also found several other genes associated with PTC risk. The study highlights the potential role of GALNT9 and other genes in PTC predisposition and emphasizes the need for large collaborations and innovative approaches to understand the genetic heterogeneity of PTC predisposition.

CANCERS (2023)

Article Oncology

Insights into Melanoma Clinical Practice: A Perspective for Future Research

Giang T. Lam, Carmela Martini, Tiffany Brooks, Sarita Prabhakaran, Ashley M. Hopkins, Ben S. -Y. Ung, Jingying Tang, Maria C. Caruso, Robert D. Brooks, Ian R. D. Johnson, Alexandra Sorvina, Shane M. Hickey, Litsa Karageorgos, Sonja Klebe, John J. O'Leary, Douglas A. Brooks, Jessica M. Logan

Summary: Early diagnosis is crucial for improving outcomes in melanoma patients, and this study aims to understand the challenges faced by clinicians in assessing melanoma cases and provide insights for future research. The survey results indicate the need for new biomarkers and the use of multiple immunohistochemistry markers to improve diagnostic accuracy in melanoma assessment.

CANCERS (2023)

No Data Available